KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Bionano Genomics (BNGO) Depreciation and Depletion (2024)

Bionano Genomics (BNGO) has disclosed Depreciation and Depletion for 1 consecutive years, with $5.4 million as the latest value for Q4 2024.

Quarterly Depreciation and Depletion changed N/A to $5.4 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $5.4 million through Jun 2025, changed N/A year-over-year, with the annual reading at $4.2 million for FY2025, 14.29% down from the prior year.
Depreciation and Depletion hit $5.4 million in Q4 2024 for Bionano Genomics, up from -$500000.0 in the prior quarter.
In the past five years, Depreciation and Depletion ranged from a high of $5.4 million in Q4 2024 to a low of -$500000.0 in Q1 2024.